Back to top
more

Amgen (AMGN)

(Real Time Quote from BATS)

$332.63 USD

332.63
488,756

+1.62 (0.49%)

Updated Aug 30, 2024 01:20 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.68%
2Buy17.55%
3Hold9.21%
4Sell4.93%
5Strong Sell2.36%
S&P50010.96%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

C Value C Growth F Momentum D VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 33% (83 out of 251)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Thousand Oaks, CA-based Amgen is one of the biggest biotech companies in the world, with a strong presence in the oncology/hematology, cardiovascular disease, neuroscience, inflammation, bone health and nephrology markets. The company used advances in cellular and molecular biology to develop two of the biotech industry’s earliest and most successful drugs, Epogen (anemia) and Neupogen (white blood cell stimulant). Amgen successfully launched two next-generation products, Aranesp and Neulasta. Meanwhile, the acquisition of Immunex Corporation gave Amgen access to the multi-blockbuster drug, Enbrel. However, all these older drugs are facing declining sales due to biosimilar or branded competition, which is being somewhat offset by its newer blockbuster drugs like Prolia/Xgeva

Should You Invest in the VanEck Biotech ETF (BBH)?

by Zacks Equity Research

Sector ETF report for BBH

Mirati (MRTX) Gets Buyout Offer From Bristol Myers for $4.8B

by Zacks Equity Research

Sanofi (SNY) is set to acquire Mirati (MRTX) for $58 per share in cash along with a contingent value right of $12 per share, tied to a regulatory milestone.

Coherus (CHRS) Stock Rises on BLA Re-Filing for Udenyca Onbody

by Zacks Equity Research

Coherus (CHRS) resubmits biologics license application for Udenyca Onbody, an on-body injector presentation of Udenyca to the FDA. Stock rises.

Santanu Roy headshot

Beat the Market the Zacks Way: UnitedHealth, Novo Nordisk, Check Point Software in Focus

by Santanu Roy

Last week, our time-tested methodologies served investors well in navigating the market. Check out some of our achievements from the past three months.

Amgen (AMGN) Increases Yet Falls Behind Market: What Investors Need to Know

by Zacks Equity Research

Amgen (AMGN) closed at $267.47 in the latest trading session, marking a +0.9% move from the prior day.

Mirati (MRTX) Surges 45% as Sanofi Reportedly Eyes Buyout

by Zacks Equity Research

A Bloomberg article suggests that pharma giant Sanofi (SNY) is exploring a potential acquisition deal for small cancer drugmaker Mirati Therapeutics (MRTX).

Amgen Inc. (AMGN) is Attracting Investor Attention: Here is What You Should Know

by Zacks Equity Research

Recently, Zacks.com users have been paying close attention to Amgen (AMGN). This makes it worthwhile to examine what the stock has in store.

The Zacks Analyst Blog Highlights Amgen, ServiceNow, RTX, Automatic Data Processing and Canadian Pacific Kansas City

by Zacks Equity Research

Amgen, ServiceNow, RTX, Automatic Data Processing and Canadian Pacific Kansas City are included in this Analyst Blog.

Amgen (AMGN) Surpasses Market Returns: Some Facts Worth Knowing

by Zacks Equity Research

Amgen (AMGN) reachead $265.44 at the closing of the latest trading day, reflecting a +1.7% change compared to its last close.

Sheraz Mian headshot

Top Research Reports for Amgen, ServiceNow & RTX

by Sheraz Mian

Today's Research Daily features new research reports on 16 major stocks, including Amgen Inc. (AMGN), ServiceNow, Inc. (NOW) and RTX Corporation (RTX).

Abhinab Dasgupta headshot

Take the Zacks Approach to Beat the Market: Shopify, Caterpillar, Amgen in Focus

by Abhinab Dasgupta

Our time-tested methodologies were at work to help investors navigate the market well last week. Here are some of our key performance data from the past three months.

Kinjel Shah headshot

3 Stocks to Focus on as Demand for Obesity Drugs Booms

by Kinjel Shah

With the obesity market gaining popularity, analysts are expecting sales to increase. Pharma companies are rushing to enter the market

Is iShares Biotechnology ETF (IBB) a Strong ETF Right Now?

by Zacks Equity Research

Smart Beta ETF report for IBB

Amgen (AMGN) Outpaces Stock Market Gains: What You Should Know

by Zacks Equity Research

In the latest trading session, Amgen (AMGN) closed at $270.82, marking a +0.68% move from the previous day.

Amgen (AMGN) Stock Sinks As Market Gains: What You Should Know

by Zacks Equity Research

In the latest trading session, Amgen (AMGN) closed at $268.98, marking a -0.02% move from the previous day.

Coherus (CHRS) Gets CRL for Udenyca Onbody, Shares Down

by Zacks Equity Research

Coherus (CHRS) gets CRL for the biologics license application supplement for Udenyca Onbody, an on-body injector presentation of Udenyca.

Amgen Inc. (AMGN) Is a Trending Stock: Facts to Know Before Betting on It

by Zacks Equity Research

Amgen (AMGN) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.

Abhinab Dasgupta headshot

Beat the Market Like Zacks: Elementis, Novo Nordisk, Amgen in Focus

by Abhinab Dasgupta

Last week, our time-tested methodologies served investors well in navigating the market. Check out some of our achievements from the past three months.

Should You Invest in the Invesco Pharmaceuticals ETF (PJP)?

by Zacks Equity Research

Sector ETF report for PJP

Amgen (AMGN) Stock Moves -0.76%: What You Should Know

by Zacks Equity Research

In the latest trading session, Amgen (AMGN) closed at $269.41, marking a -0.76% move from the previous day.

Should You Invest in the iShares Biotechnology ETF (IBB)?

by Zacks Equity Research

Sector ETF report for IBB

Abhinab Dasgupta headshot

Beat the Market the Zacks Way: Automatic Data Processing, Casey's, Paysafe in Focus

by Abhinab Dasgupta

Our time-tested methodologies were at work to help investors navigate the market well last week. Here are some of our key performance data from the past three months.

Amgen (AMGN) Outpaces Stock Market Gains: What You Should Know

by Zacks Equity Research

In the latest trading session, Amgen (AMGN) closed at $262.30, marking a +1.97% move from the previous day.

AbbVie's (ABBV) Skyrizi Crohn's Disease Study Meets Goals

by Zacks Equity Research

AbbVie's (ABBV) Skyrizi met both primary endpoints of non-inferiority for clinical remission at week 24 and superiority of endoscopic remission at week 48 versus J&J's Stelara in a head-to-head study.

Investors Heavily Search Amgen Inc. (AMGN): Here is What You Need to Know

by Zacks Equity Research

Amgen (AMGN) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.